Foundation Medicine reported after the close of the market yesterday that its fourth quarter revenues climbed 87 percent to $9.7 million from $5.2 million in the fourth quarter of 2013, and it reported results from more than 3,750 of its cancer tests during the quarter.

The Cambridge, Mass.-based cancer genomic analysis firm launched its next-gen sequencing-based solid tumor test, FoundationOne, which screens over 200 cancer-related genes last year, and launched a second product, FoundationOne Heme, for blood-based cancers last December.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Cell this week: dynamics of protein profusion and localization, melanoma classification schemes, and more.

A company says it can generate likenesses of people based on their genetic profiles.

IBM's Watson is learning how to treat leukemia as a fellow at the MD Anderson Cancer Center, according to the Washington Post.

In PNAS this week: ancestry and admixture in Brazilians, characterization of novel double-stranded RNA mycovirus, and more.

Jul
14
Sponsored by
Agilent Technologies

This online seminar will outline a recent example of the use of molecular barcoding in combination with next-generation sequencing to detect somatic mosaicism in cancer patients.